
Lei Yao
Examiner (ID: 12775, Phone: (571)272-3112 , Office: P/1642 )
| Most Active Art Unit | 1642 |
| Art Unit(s) | 1642 |
| Total Applications | 1328 |
| Issued Applications | 662 |
| Pending Applications | 127 |
| Abandoned Applications | 552 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18837738
[patent_doc_number] => 11845801
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-12-19
[patent_title] => IL-15 prodrugs and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 16/900677
[patent_app_country] => US
[patent_app_date] => 2020-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 36
[patent_no_of_words] => 18813
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 160
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16900677
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/900677 | IL-15 prodrugs and methods of use thereof | Jun 11, 2020 | Issued |
Array
(
[id] => 16328423
[patent_doc_number] => 20200299389
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-24
[patent_title] => Bifunctional Proteins Combining Checkpoint Blockade for Targeted Therapy
[patent_app_type] => utility
[patent_app_number] => 16/896597
[patent_app_country] => US
[patent_app_date] => 2020-06-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9314
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 35
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16896597
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/896597 | Bifunctional proteins combining checkpoint blockade for targeted therapy | Jun 8, 2020 | Issued |
Array
(
[id] => 16539462
[patent_doc_number] => 20200405875
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-31
[patent_title] => CKIT ANTIBODY DRUG CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 16/893359
[patent_app_country] => US
[patent_app_date] => 2020-06-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44680
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16893359
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/893359 | CKIT antibody drug conjugates | Jun 3, 2020 | Issued |
Array
(
[id] => 16310894
[patent_doc_number] => 20200289632
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS
[patent_app_type] => utility
[patent_app_number] => 16/887815
[patent_app_country] => US
[patent_app_date] => 2020-05-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35184
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 111
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16887815
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/887815 | A*03 restricted peptides for use in immunotherapy against cancers and related methods | May 28, 2020 | Issued |
Array
(
[id] => 16312350
[patent_doc_number] => 20200291088
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-17
[patent_title] => NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS
[patent_app_type] => utility
[patent_app_number] => 16/887994
[patent_app_country] => US
[patent_app_date] => 2020-05-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52059
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 143
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16887994
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/887994 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | May 28, 2020 | Issued |
Array
(
[id] => 16507502
[patent_doc_number] => 20200386758
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-10
[patent_title] => GDF-15 AS A DIAGNOSTIC MARKER FOR MELANOMA
[patent_app_type] => utility
[patent_app_number] => 16/876482
[patent_app_country] => US
[patent_app_date] => 2020-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27192
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16876482
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/876482 | GDF-15 AS A DIAGNOSTIC MARKER FOR MELANOMA | May 17, 2020 | Abandoned |
Array
(
[id] => 17704637
[patent_doc_number] => 20220204643
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => CANCER ASSOCIATED ANTIBODY COMPOSITIONS AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 17/606246
[patent_app_country] => US
[patent_app_date] => 2020-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 374540
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -99
[patent_words_short_claim] => 34
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17606246
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/606246 | Cancer associated antibody compositions and methods of use | Apr 28, 2020 | Issued |
Array
(
[id] => 17867119
[patent_doc_number] => 20220289854
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-15
[patent_title] => METHODS FOR TREATING CANCER USING COMBINATIONS OF ANTI-CX3CR1 AND IMMUNE CHECKPOINT BLOCKADE AGENTS
[patent_app_type] => utility
[patent_app_number] => 17/606585
[patent_app_country] => US
[patent_app_date] => 2020-04-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 66320
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -62
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17606585
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/606585 | METHODS FOR TREATING CANCER USING COMBINATIONS OF ANTI-CX3CR1 AND IMMUNE CHECKPOINT BLOCKADE AGENTS | Apr 23, 2020 | Pending |
Array
(
[id] => 17112113
[patent_doc_number] => 20210292710
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-23
[patent_title] => METHOD FOR ENHANCING IMMUNE FUNCTION OF IMMUNE CELL AND IMMUNE CELL LINE PRODUCED USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 16/833011
[patent_app_country] => US
[patent_app_date] => 2020-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11734
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 40
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16833011
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/833011 | METHOD FOR ENHANCING IMMUNE FUNCTION OF IMMUNE CELL AND IMMUNE CELL LINE PRODUCED USING THE SAME | Mar 26, 2020 | Abandoned |
Array
(
[id] => 16507505
[patent_doc_number] => 20200386761
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-10
[patent_title] => SPECIFIC BIOMARKER SET FOR NON-INVASIVE DIAGNOSIS OF LIVER CANCER
[patent_app_type] => utility
[patent_app_number] => 16/825515
[patent_app_country] => US
[patent_app_date] => 2020-03-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9505
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 84
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16825515
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/825515 | SPECIFIC BIOMARKER SET FOR NON-INVASIVE DIAGNOSIS OF LIVER CANCER | Mar 19, 2020 | Abandoned |
Array
(
[id] => 16328438
[patent_doc_number] => 20200299404
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-24
[patent_title] => Method for providing personalized cells with chimeric antigen receptors (CAR)
[patent_app_type] => utility
[patent_app_number] => 16/823012
[patent_app_country] => US
[patent_app_date] => 2020-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5871
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 149
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16823012
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/823012 | Method for providing personalized cells with chimeric antigen receptors (CAR) | Mar 17, 2020 | Pending |
Array
(
[id] => 16614959
[patent_doc_number] => 20210033612
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-04
[patent_title] => METHODS OF USING NON-RARE CELLS TO DETECT RARE CELLS
[patent_app_type] => utility
[patent_app_number] => 16/819684
[patent_app_country] => US
[patent_app_date] => 2020-03-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14586
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16819684
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/819684 | METHODS OF USING NON-RARE CELLS TO DETECT RARE CELLS | Mar 15, 2020 | Abandoned |
Array
(
[id] => 16087085
[patent_doc_number] => 20200197529
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-25
[patent_title] => ANTIGEN BINDING PROTEINS
[patent_app_type] => utility
[patent_app_number] => 16/815677
[patent_app_country] => US
[patent_app_date] => 2020-03-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32272
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 50
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16815677
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/815677 | Antigen binding proteins | Mar 10, 2020 | Issued |
Array
(
[id] => 16284748
[patent_doc_number] => 20200278350
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-09-03
[patent_title] => COMPOSITIONS AND METHODS FOR DETERMIINNG CANCER PROGNOSIS
[patent_app_type] => utility
[patent_app_number] => 16/805464
[patent_app_country] => US
[patent_app_date] => 2020-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15896
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16805464
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/805464 | Compositions and methods for determining cancer prognosis | Feb 27, 2020 | Issued |
Array
(
[id] => 16756610
[patent_doc_number] => 10975147
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-04-13
[patent_title] => Modified J-chain
[patent_app_type] => utility
[patent_app_number] => 16/803745
[patent_app_country] => US
[patent_app_date] => 2020-02-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 19
[patent_no_of_words] => 17063
[patent_no_of_claims] => 28
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16803745
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/803745 | Modified J-chain | Feb 26, 2020 | Issued |
Array
(
[id] => 18289907
[patent_doc_number] => 11618770
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-04
[patent_title] => MUC1-derived peptide, and pharmaceutical composition for treatment or prevention of cancer, immunity-inducing agent and method for manufacturing antigen presenting cell using same
[patent_app_type] => utility
[patent_app_number] => 16/795391
[patent_app_country] => US
[patent_app_date] => 2020-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 4
[patent_no_of_words] => 6851
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 90
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16795391
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/795391 | MUC1-derived peptide, and pharmaceutical composition for treatment or prevention of cancer, immunity-inducing agent and method for manufacturing antigen presenting cell using same | Feb 18, 2020 | Issued |
Array
(
[id] => 17625875
[patent_doc_number] => 20220160890
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-26
[patent_title] => SURVIVAL-TARGETING CHIMERIC (SURTAC) MOLECULES
[patent_app_type] => utility
[patent_app_number] => 17/426141
[patent_app_country] => US
[patent_app_date] => 2020-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18966
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17426141
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/426141 | SURVIVAL-TARGETING CHIMERIC (SURTAC) MOLECULES | Feb 18, 2020 | Pending |
Array
(
[id] => 15993511
[patent_doc_number] => 20200172626
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-06-04
[patent_title] => ANTI-HUMAN 4-1BB ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/790299
[patent_app_country] => US
[patent_app_date] => 2020-02-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32196
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16790299
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/790299 | Anti-human 4-1BB antibodies and uses thereof | Feb 12, 2020 | Issued |
Array
(
[id] => 16141465
[patent_doc_number] => 10703795
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2020-07-07
[patent_title] => Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
[patent_app_type] => utility
[patent_app_number] => 16/778915
[patent_app_country] => US
[patent_app_date] => 2020-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 29
[patent_figures_cnt] => 31
[patent_no_of_words] => 53002
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 131
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16778915
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/778915 | Peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers | Jan 30, 2020 | Issued |
Array
(
[id] => 17482270
[patent_doc_number] => 20220089774
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-24
[patent_title] => MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO CCSP-2 AND USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/310296
[patent_app_country] => US
[patent_app_date] => 2020-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12183
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 324
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17310296
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/310296 | Monoclonal antibody specifically binding to CCSP-2 and use thereof | Jan 28, 2020 | Issued |